Jump to content

CD226

From Wikipedia, the free encyclopedia
CD226
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCD226, DNAM-1, DNAM1, PTA1, TLiSA1, CD226 molecule
External IDsOMIM: 605397; MGI: 3039602; HomoloGene: 4787; GeneCards: CD226; OMA:CD226 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

10666

225825

Ensembl

ENSG00000150637

ENSMUSG00000034028

UniProt

Q15762

Q8K4F0

RefSeq (mRNA)

NM_001303618
NM_001303619
NM_006566

NM_001039148
NM_001039149
NM_178687

RefSeq (protein)

NP_001290547
NP_001290548
NP_006557

NP_001034238
NP_848802

Location (UCSC)Chr 18: 69.83 – 69.96 MbChr 18: 89.2 – 89.29 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

CD226 (Cluster of Differentiation 226), PTA1 (outdated term, 'platelet and T cell activation antigen 1')[5] or DNAM-1 (DNAX Accessory Molecule-1)[5] is a ~65 kDa  immunoglobulin-like transmembrane glycoprotein expressed on the surface of natural killer cells, NK T cell, B cells, dendritic cells, hematopoietic precursor cells, platelets, monocytes and T cells.[6]

DNAM-1 gene CD226 is conserved between human and mice. In humans the CD226 gene is located on chromosome 18q22.3.[7] In mice the CD226 gene is located on chromosome 18E4.

Structure

[edit]

DNAM-1 is composed of three domains: an extracellular domain of 230 amino acids with two immunoglobin-like V-set domains and eight N-glycosylation sites, a transmembrane domain of 28 amino acids and a cytosolic domain of 60 amino acids containing four putative tyrosine residues and one serine residue for phosphorylation.[8]

Signaling

[edit]

Upon engagement to its ligand, DNAM-1 is phosphorylated by protein kinase C. Then adhesive molecule LFA-1 crosslinks with DNAM-1 that results in recruitment of DNAM-1 to lipid rafts and promotes association with actin cytoskeleton. Cross-linking with LFA-1 also induce phosphorylation on Tyr128 and Tyr113 by Fyn Src kinase.[9]

DNAM-1 and CD244 together promotes phosphorylation of SH2 domain of SLP-76. This leads to activation of phospholipase Cγ2, Ca2+ influx, cytoskeletal reorganization, degranulation, and secretion.[8]

Function

[edit]

DNAM-1 mediates cellular adhesion to other cells bearing its ligands, nectin molecule CD112 and nectin-like protein CD155,[10][11] that are broadly distributed on normal neuronal, epithelial, fibroblastic cells, dendritic cells, monocytes and on infected or transformed cells.

DNAM-1 promotes lymphocyte signaling, lymphokine secretion and cytotoxicity of NK cells and cytotoxic CD8+ T lymphocytes.[6] Cross-linking of DNAM-1 with antibodies causes cellular activation.[7]

DNAM-1 participates on platelets activation and aggregation.[8]

DNAM-1 possibly plays a role in trans-endothelial migration of NK cells because it was shown that monoclonal antibodies against DNAM-1 or CD155 inhibit this process.[9]

DNAM-1 interaction with its ligands promotes killing of immature and mature dendritic cells, is involved in the crosstalk between NK cells and T lymphocytes and can lyse activated T lymphocytes during graft versus host disease (GvHD).[8][9]

DNAM-1 also participates in the immunological synapse where is colocalized with LFA-1.[9]

DNAM-1 regulation

[edit]

DNAM-1 expression on NK cells can be regulated by cell-cell interaction and by soluble factors. In human, IL-2 and IL-15 up-regulate DNAM-1 expression, whereas TGF-β, indolamine 2,3-dioxygenase and chronic exposure to CD155 can down-regulate DNAM-1 expression on NK cells.[9]

DNAM-1 and NK cells

[edit]

DNAM is involved in NK cell education, differentiation, cytokine production and immune synapse formation. DNAM-1 exerts synergistic roles in NK cells regulation with three molecules that are TIGIT, CD96 and CRTAM.[9]  

Cytotoxic response of NK cells might require synergistic activation from specific pairs of receptors. DNAM-1 could synergize with SLAM family member 2B4 (CD244) or with other receptors to induce full NK cell activation.[8]

DNAM-1 in cancer

[edit]

The role of DNAM-1 in tumor environment was firstly described in vivo using RMA lymphoma model. In this model, enforced expression of DNAM-1 ligands CD155 and CD112 increased tumor rejection. CD155 and CD112 are expressed on the surface of a wide number of tumor cells in solid and lymphoid malignances such as lung carcinoma, primary human leukemia, myeloma, melanoma, neuroblastoma, ovarian cancer, colorectal carcinoma, and Ewing sarcoma cells.[9]

The role of DNAM-1 in the killing of tumor cells was supported with DNAM-/- mice model that was more susceptible to formation of spontaneous fibrosarcoma.[8]  

It was shown that NK cells can kill leukemia and neuroblastoma cells expressing CD155 and block of CD155 or DNAM-1 results in inhibition of tumor cells lysis.[9]

In vivo, tumor cells are capable of evading DNAM-1 tumor suppressing mechanisms. Tumor cells can downregulate CD155 or CD112 to disable recognition of these DNAM-1 ligands. The other mechanism is a downregulation of DNAM-1 from the effector NK cell surface due to the chronic ligand (CD155) exposure.[9]

DNAM-1 was also used in T lymphocytes with a chimeric antigen receptors (CAR) for the treatment of cancer.[12]

DNAM-1 and infections

[edit]

DNAM-1 has a relevant role in the process of recognizing virus-infected cells during early infection for example in case of cytomegalovirus infection by NK cells. DNAM-1 ligands are also expressed in antigen-presenting cells activated by toll-like receptors and CD155 might be activated by DNA-damage response as was demonstrated for human immunodeficiency virus (HIV).[8]

DNAM-1 functionality during infections may be impaired by viral immune evasion mechanisms. Viruses can downregulate production of surface CD112 and CD155 and thus avoid recognition of DNAM-1 expressed on NK cells. The other way is downregulation of DNAM-1 expressions that may occur during chronic infections.[8]

NK cells activated with interferon α can kill HCV-infected cells in a DNAM-1 dependent manner.[13]

During the bacterial infection interaction between DNAM-1 and its ligands helps to mediate the migration of leukocytes from the blood to secondary lymphoid organs or into inflamed tissues.[9]

Soluble DNAM-1

[edit]

It is suggested that soluble DNAM-1 is a prognostic marker in some types of cancer and in graft-versus-host-disease and that soluble DNAM-1 might play role in pathogenesis of some autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis and rheumatoid arthritis.[14]

See also

[edit]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000150637 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000034028 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b Fuchs A, Colonna M (October 2006). "The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance". Seminars in Cancer Biology. 16 (5): 359–366. doi:10.1016/j.semcancer.2006.07.002. PMID 16904340.
  6. ^ a b Huang Z, Qi G, Miller JS, Zheng SG (2020-07-24). "CD226: An Emerging Role in Immunologic Diseases". Frontiers in Cell and Developmental Biology. 8: 564. doi:10.3389/fcell.2020.00564. PMC 7396508. PMID 32850777.
  7. ^ a b "Entrez Gene: CD226 CD226 molecule".
  8. ^ a b c d e f g h de Andrade LF, Smyth MJ, Martinet L (March 2014). "DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins". Immunology and Cell Biology. 92 (3): 237–244. doi:10.1038/icb.2013.95. PMID 24343663. S2CID 57669.
  9. ^ a b c d e f g h i j Xiong P, Sang HW, Zhu M (November 2015). "Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity". Immunology. 146 (3): 369–378. doi:10.1111/imm.12516. PMC 4610626. PMID 26235210.
  10. ^ Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. (August 2003). "Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule". The Journal of Experimental Medicine. 198 (4): 557–567. doi:10.1084/jem.20030788. PMC 2194180. PMID 12913096.
  11. ^ Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A, et al. (April 2004). "Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)". International Immunology. 16 (4): 533–538. doi:10.1093/intimm/dxh059. hdl:2241/102014. PMID 15039383.
  12. ^ Wu MR, Zhang T, Alcon A, Sentman CL (April 2015). "DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma". Cancer Immunology, Immunotherapy. 64 (4): 409–418. doi:10.1007/s00262-014-1648-2. PMC 4370794. PMID 25549845.
  13. ^ Stegmann KA, Björkström NK, Ciesek S, Lunemann S, Jaroszewicz J, Wiegand J, et al. (May 2012). "Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1". The Journal of Infectious Diseases. 205 (9): 1351–1362. doi:10.1093/infdis/jis210. PMC 3690562. PMID 22457290.
  14. ^ Nakano M, Ayano M, Kushimoto K, Kawano S, Higashioka K, Inokuchi S, et al. (August 2021). "Association of elevated serum soluble CD226 levels with the disease activity and flares of systemic lupus erythematosus". Scientific Reports. 11 (1): 16162. Bibcode:2021NatSR..1116162N. doi:10.1038/s41598-021-95711-2. PMC 8352936. PMID 34373559.

Further reading

[edit]
[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=CD226&oldid=1257357893"